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Objective. Similar to patients with systemic lupus
erythematosus, autoimmune MRL/lpr mice spontane-
ously develop behavioral deficits and pathologic
changes in the brain. Given that the disease-associated
brain atrophy in this model is not well understood, the
present study was undertaken to determine the time
course of morphometric changes in major brain struc-
tures of autoimmune MRL/lpr mice.
Methods. Computerized planimetry and high-
resolution magnetic resonance imaging (MRI) were
used to compare the areas and volumes of brain struc-
tures in cohorts of mice that differ in severity of
lupus-like disease.
Results. A thinner cerebral cortex and smaller
cerebellum were observed in the MRL/lpr substrain,
even before severe autoimmunity developed. With pro-
gression of the disease, the brain area of coronal
sections became smaller and the growth of the hip-
pocampus was retarded, which likely contributed to the
increase in the ventricle area:brain area ratio. MRI
revealed reduced volume across different brain regions,
with the structures in the vicinity of the ventricular
system particularly affected. The superior colliculus,
periaqueductal gray matter, pons, and midbrain were
among the regions most affected, whereas the volumes
of the parietal-temporal lobe, parts of the cerebellum,
and lateral ventricles in autoimmune MRL/lpr mice
were comparable with values in congenic controls.
Conclusion. These results suggest that morpho-
logic alterations in the brains of MRL/lpr mice are a
consequence of several factors, including spontaneous
development of lupus-like disease. A periventricular
pattern of parenchymal damage is consistent with the
cerebrospinal fluid neurotoxicity, limbic system patho-
logic features, and deficits in emotional reactivity pre-
viously documented in this model.
Neuropsychiatric (NP) manifestations are a com-
mon and serious complication of systemic lupus ery-
thematosus (SLE). Contemporary imaging techniques
have revealed various abnormalities in patients with
SLE, including lesions in the periventricular and subcor-
tical regions (1,2), hypoperfusion (3), and regional met-
abolic abnormalities (4). Brain atrophy is the most
frequent observation (5) and is likely a consequence of
widespread neuronal and glial damage (6). Consistent
with these reports, recent studies on water diffusivity
indicate a genuine loss of brain-tissue integrity in pa-
tients with NPSLE/central nervous system (CNS) lupus
(7). However, the lack of understanding of CNS damage
led to development of animal models of acute and
chronic lupus and dissection of complex pathogenic
circuits (8).
MRL/MpJTnfrsf6lpr (MRL/lpr) mice and MRL/
MpJ/ (MRL/) congenic control mice share more
than 99.9% of their genome but differ in the onset of
lupus-like manifestations. The 3–4-month difference in
the time to onset allows discrimination of autoimmunity-
induced functional and structural brain damage from
epiphenomena associated with aging and with damage of
vital peripheral organs (9). In addition to accelerated
development of serologic signs of inflammation and
autoimmunity, MRL/lpr mice develop, at an early stage,
a constellation of behavioral deficits and neuropatho-
logic changes, operationally termed autoimmune-
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associated behavioral syndrome (AABS). In models of
CNS lupus, AABS has been shown to have significant
face, construct, and predictive validity (10). In particu-
lar, reduced complexity of pyramidal neurons, retarded
brain growth (11,12), increased TUNEL staining (13),
Fluoro Jade B positivity (14), and increased ubiquitina-
tion in the cerebral cortex and limbic system (15) are all
manifestations that point to profound neurodegenera-
tion in the brain parenchyma of these mice. The com-
mon occurrence of enlarged ventricles in diseased MRL/
lpr mice further supports the causal link between
systemic autoimmunity and loss of brain tissue (16,17).
CNS lupus has focal, diffuse, and complex forms
of presentation. The focal form is characterized by
cerebral infarctions and peripheral neuropathies, while
the diffuse form is often associated with brain atrophy,
psychiatric manifestations, and cognitive decline; the
complex form involves manifestations of both disease
types. To understand the nature of brain atrophy in the
MRL mouse model, it is important to elucidate its time
course and whether the loss of brain parenchyma is
either generalized or selected. Previous evidence from
behavioral and neuropathologic studies points to the
periventricular region and the nearby limbic structures
as primary targets of intrathecal autoimmune activity
(15,18–21). Although neuronal damage was also noted
in the cortical and cerebellar areas, it was neither
quantified nor compared with damage in other brain
regions (14).
The aim of the present study was to assess
regional changes in the brains of MRL substrains of
mice during the progression of lupus-like disease. In the
first experiment, digital planimetry was used to measure
the areas of major brain structural changes in cohorts of
differing age and varying disease severity. In the second
experiment, high-resolution magnetic resonance imag-
ing (MRI) was used to examine volumetric differences in
specific brain regions and nuclei. The overall expecta-
tion was that changes in the limbic system will be
detected at the onset of autoimmune disease, when
anxiety-related and depression-like behavioral deficits
emerge in MRL/lpr mice (18,20).
MATERIALS AND METHODS
Assessment of the time course of planimetric changes
in major brain structures (experiment 1). Animals and tissue
collection. Infiltrated immunocytes can be seen in the choroid
plexus of some MRL/lpr mice as young as age 8 weeks (22).
Given that the median life span of this substrain is 20 weeks,
these time points were used to assign cohorts into 3 general age
groups for the assessment of the time course of gross morpho-
logic changes. In particular, 5–8-week-old mice were assigned
to the young age group, 9–20-week-old mice were assigned to
the middle age group, and mice older than age 20 weeks were
assigned to the old age group.
Eighty-one MRL/lpr mice and 47 MRL/ mice,
ranging in age from 5 weeks to 48 weeks, were originally
purchased at 4 weeks of age from The Jackson Laboratory
(Bar Harbor, ME) to measure organ weights. Of this group, 39
MRL/lpr mice and 26 MRL/ mice of both sexes were also
used for planimetric analysis. Mice were housed in groups of 4
per cage and were kept under standard laboratory conditions
(light period from 7:00 AM to 7:00 PM, room temperature
21°C, humidity 62%, regular rodent chow and tap water ad
libitum, bedding changed every 3–4 days). Many of the MRL/
lpr mice older than age 3 months developed overt symptoms,
as evidenced by lymph node enlargement, necrotic ear tips,
dermatitis, and alopecia.
Mice were anesthetized with an intraperitoneal injec-
tion of pentobarbital sodium (Somnotol; 65 mg/kg, 0.15–0.2
ml) and their body weight was recorded. After intracardial
perfusion with 40 ml phosphate buffered saline (PBS), the
brains were removed within 2 minutes and weighed on a digital
scale (Mettler Toledo AB54-S; VWR Scientific of Canada,
Mississauga, Ontario, Canada). The brains were then im-
mersed into 4% paraformaldehyde and transferred 48 hours
later into bottles with 30% sucrose–PBS. Given that spleno-
megaly is a hallmark of lupus-like disease in the MRL/lpr
substrain, the wet spleen weight was measured upon extrac-
tion. All experimental protocols were approved by a local
animal care committee and carried out in accordance with the
rules and regulations of the Canadian Council of Animal Care.
Planimetric analysis. Sealed bottles were sent by courier
to NeuroScience Associates Laboratory (Knoxville, TN) for
sectioning and staining of the mouse brains. Twenty mouse
brains were leveled, embedded in a gelatin block, and simul-
taneously cut coronally. The sections were processed using a
standard hematoxylin and eosin staining protocol. Slides were
examined under a laser scanning microscope (LSM 510; Zeiss,
Wetzlar, Germany). Digital images were obtained with a
10/0.63 objective and Nikon digital camera at a resolution of
1,024  1,024 pixels, and subsequently traced with Axiovision
software, version 4.5 (Zeiss). The areas of interest included the
entire brain area, the thickness of the motor, sensory, and
piriform cortices, and the areas of the lateral ventricles,
hippocampus, and cerebellum. A standard atlas of the mouse
brain was used for locating specific cerebral and cerebellar
regions.
The brain area was assessed on 16 sections at the
following approximate locations (in mm from Bregma): 2.34,
2.22, 1.18, 0.98, 0.02, 0.22, 0.70, 1.22, 1.70, 1.94,
2.18, 2.70, 3.40, 3.52, 4.16, and 4.32. These sections
were selected because they were undamaged on all brains
examined. For the first 2 sections, the shapes of the medial
orbital cortex and the intrabulbar commissure (anterior part)
were used as landmarks. In the subsequent 7 sections, the size
and shape of the lateral ventricles were used for slice compar-
isons. In the posterior 7 sections, the size and shape of the
hippocampus were used to match sections from different
brains.
The thickness of the secondary (M2) and primary (M1)
motor cortices, the sensory cortex, and the piriform cortex was
measured bilaterally on 6 sections, at the following approxi-
mate locations (in mm from Bregma): 1.18, 0.98, 0.02, 0.22,
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0.70, and 1.22. The cortical surface was the starting point,
while the ending points were the cingulum, dorsal end of the
external capsule, laterodorsal striatum, and ventral endopiri-
form nucleus, respectively. The left and right lateral ventricles
were traced on 3 sections, at 1.18, 0.70, and 1.22 mm from
Bregma. The left and right hippocampi were measured on 6
planes, at 1.70, 1.94, 2.18, 3.40, 3.64, and 4.16 mm
from Bregma. The hippocampi were flanked by the corpus
callosum on the dorsal side, lateral ventricle and fimbria on the
lateral side, and the third ventricle on the medial side. The
cerebellum was measured on 5 sections, at 5.80, 6.00,
6.12, 6.24, and 6.48 mm from Bregma. The tracing
included the fourth and fifth cerebellar lobules, tenth cerebel-
lar lobule, inferior cerebellar peduncle, simple lobule, Crus-1
and -2 of ansiform lobules, and paraflocculus. The fourth
ventricle was used as a landmark for the ventral boundary of
the cerebellum.
Statistical analysis. The data were analyzed by two-way
analysis of variance (ANOVA). The between-group factors
were substrain (MRL/lpr versus MRL/) and age (young,
middle, and old), while values obtained from different sections
or hemispheres in the same mouse were treated as repeated
measures. Student’s t-test was used in the post hoc group
comparison. Pearson’s and Spearman’s correlation procedures
were used to measure associations between dependent vari-
ables. All computations were performed with SPSS software
(version 13; SPSS, Chicago, IL) and FigP software (version
2.98; Biosoft, Cambridge, UK). Results of brain planimetry are
expressed as the mean  SEM. P values less than 0.05 were
considered significant.
Assessment of volumetric differences by MRI (experi-
ment 2). Animals and sample preparation. Based on the signif-
icant group differences that were revealed by brain planimetry,
separate cohorts of adult MRL/lpr and MRL/ mice were
used to study volumetric differences in 3-dimensionally de-
fined brain regions. High-resolution MRI was used to deter-
mine the volumes of 62 regions, which were identified with
reference to a standard atlas of the mouse brain.
This experiment was conducted on a cohort of 12-
week-old MRL/lpr (n  14) and MRL/ (n  17) male mice,
born in colonies at McMaster University and The Jackson
Laboratory. Mice were housed under the same conditions as
described in experiment 1. Body and spleen weights were
recorded at the time that the mice were killed. The mice were
anesthetized with a combination of ketamine (100 mg/kg;
Pfizer, Kirkland, Quebec, Canada) and rompun (20 mg/kg;
Bayer, Toronto, Ontario, Canada) via intraperitoneal injec-
tion. The thoracic cavities were exposed, and 30 ml of PBS, pH
7.4, kept at room temperature, was infused at a rate of 100
ml/hour through the left ventricle. This was followed by
infusion with 30 ml of iced 4% paraformaldehyde in PBS at the
same rate. Following perfusion, the heads were removed along
with the skin, lower jaw, ears, and cartilaginous nose tip. The
remaining skull structures were allowed to postfix in 4%
paraformaldehyde at 4°C for 12 hours. Following an incubation
period of 5 days in PBS and 0.01% sodium azide at 15°C, the
skulls were transferred to a contrast agent solution of PBS and
2 mM gadoteridol (ProHance; Bracco Diagnostics, Princeton,
NJ) for at least 7 days at 15°C. MRI was performed at least 21
days postmortem.
Imaging and processing. A multichannel 7.0-Tesla MRI
scanner (Varian, Palo Alto, CA) with a 6-cm–inner bore
diameter insert-gradient set was used to acquire anatomic
images of the brains within the skulls. Prior to imaging, the
samples were removed from the contrast agent solution,
blotted, and placed into 13-mm–diameter plastic tubes filled
with a proton-free susceptibility-matching fluid (Fluorinert
FC-77; 3M Corporation, St. Paul, MN). Three custom-built,
14-mm–diameter solenoid coils with a length of 18.3 mm and
overwound ends were used to image 3 brains in parallel. The
parameters used in the scans were optimized for grey/white
matter contrast, as follows: T2-weighted, 3-dimensional fast
spin-echo sequence, repetition time/echo time 325/32 msec,
echo train length 6, 4 averages, field of view 14  14  25 mm,
and matrix size 432  432  780 mm, giving an image with
32 m isotropic voxels. The total imaging time was 11.3 hours.
The obtained 32-m isotropic resolution T2-weighted
MRI scans were then nonlinearly aligned to a 3-dimensional
atlas of the mouse brain with 62 structures identified. As
described in more detail previously (23), this process consisted
of a 3-part registration scheme involving an initial rigid body
alignment, followed by a set of 12-parameter pairwise registra-
tions between all mice, and finally, a set of iterative nonlinear
registrations. An additional processing step was required to
adapt the above-summarized algorithm to the MRL mouse
strain. Forty percent of specimens showed a fluid layer sur-
rounding the brain that was bright on T2-weighted MR images
and that prevented accurate identification of the cortical
surface by the algorithm. This was addressed in these speci-
mens by attenuating the intensity of this layer to match that of
the surrounding meninges and skull. This step consisted of
normalizing the median image intensity of all scans, manually
training an intensity-based classifier in which fluid and paren-
chyma had Gaussian-distributed intensity models, and comput-
ing the normalized likelihood (L) map of fluid for each
specimen. Within a region 100 m inside and outside of the
initial estimate of the cortical surface, voxels with a high
likelihood of being fluid were substituted with the intensity of
the skull (Is), and voxels with intermediate likelihoods were
assigned values between the intensity of the skull and that of
the parenchyma (Ip). The exact substitution formula, based on
a normalized likelihood of L  [0, 1] and selected crispness
parameter () of 13, was
I   I(1)Is  Ip L  0.1L  0.1
where the parameter  was calculated as
 
e L1/ 2
1e L1/ 2 .
The cortical surface determined without and with this cor-
rection is illustrated in Figure 5. The volume of the iden-
tified fluid layer was retained for subsequent analysis.
Statistical analysis. The volume for each anatomic
structure defined in the atlas was computed for each mouse by
integrating the Jacobian of the transformation mapping the
atlas image to the image for that mouse. This procedure has
previously been shown to provide volume estimates compara-
ble with those obtained by standard stereologic methods using
tissue sections (24). The effect of MRL substrain (genotype)
on the volume of each structure was assessed by regression
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against a linear model with genotype as a fixed factor and body
weight as a covariate, using the software package R (http://
www.r-project.org/). The significance (chance of Type I error)
of the t-statistic associated with the genotype factor was
corrected for multiple comparisons using the false discovery
rate method (25). In addition, the relationship between brain
volume and the volume of the outside fluid layer was assessed
by ANOVA with genotype as a factor and 3 covariates, the
fluid volume, the body weight, and the fluid volume–genotype
interaction.
Local differences in brain shape related to genotype
were assessed by analysis of the deformation fields (26). For
this analysis, the transformation data were smoothed with a
0.5-mm Gaussian kernel, and the logarithm of the Jacobian
was computed for univariate statistical comparison at every
image point. The resulting t-statistic images were examined for
regions exceeding a significance threshold corresponding to a
5% false discovery rate (for a 2-tailed test).
RESULTS
Changes to major brain structures, as revealed
by planimetry in experiment 1. Although body mass was
comparable between the MRL/lpr and control mice in
the young and middle-age groups, old MRL/lpr mice
were significantly heavier than their age-matched con-
trols (substrain-by-age, F[2,122]  3.427, P  0.036; t[58]
 5.152, P 	 0.001) (Figure 1A). As expected, a steep
increase in spleen weight in the mice in the middle-age
and old groups confirmed the accelerated onset of
lupus-like disease in the MRL/lpr substrain (substrain-
by-age, F[2,122]  10.104, P 	 0.001 versus controls)
(Figure 1B). Conversely, lighter brains were observed in
all MRL/lpr mice compared with the MRL/ controls,
even those in the young age group (substrain, F[1,122] 
Figure 1. Comparison of body mass and spleen mass between MRL/lpr mice and MRL/ control mice by age group. A, Body mass was
comparable between young and middle-age MRL/lpr mice and their age-matched controls, but the cohort of old MRL/lpr mice was significantly
heavier than their controls. B, Profound splenomegaly, as indicated by significantly increased spleen mass in the middle-age and old MRL/lpr mice
compared with their controls, provided confirmation of the severe autoimmune disease in these groups. C, Brain mass was lower in the lupus-prone
MRL/lpr mice in all 3 age groups compared with their controls. D, Regression slopes of brain weight were plotted against actual age (in weeks). The
negative slope for the MRL/lpr group suggests a genuine loss of brain parenchyma with aging and disease progression. Bars in A–C show the mean
and SEM.   P 	 0.05 versus age-matched MRL/ control mice.
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91.798, P 	 0.001; age, F[2,122]  6.065, P  0.003)
(Figure 1C). The comparison of regression slopes (de-
termined using the R software package [27]) revealed a
significant between-group difference in brain mass
changes over time (t[124]  2.74, P 	 0.01), with the
slope for the MRL/lpr mice declining at an annualized
rate of 43 mg/year, compared with no significant
decline in brain mass over time in the controls (Figure
1D). No significant correlation was observed between
body mass and brain mass when mice of all groups and
all ages were considered (r[126]  0.052, P not signif-
icant [NS]).
The tracing of major brain regions (shown sche-
matically in Figures 2A and B) revealed numerous
differences between the MRL substrains at different
ages. Overall, ANOVA revealed a smaller brain area in
the MRL/lpr substrain compared with the MRL/
controls (substrain, F[1,55]  6.803, P  0.012), but this
analysis was not sensitive in detecting any significant
substrain-by-age interaction (F[2,55]  2.329, P  0.1),
likely because of the reduced sample size. However, the
t-test applied to each age group revealed that the mean
brain cross-sectional area was comparable in the young
age groups of both substrains, but was smaller in MRL/
lpr mice at ages associated with inflammation of the
brain (middle age, t[23]  3.763, P 	 0.001 versus
age-matched controls; old age, t[23]  2.084, P 
0.048 versus age-matched controls) (Figure 2C).
Figure 2. Planimetry and thickness assessments of the brain areas of MRL/lpr mice compared with MRL/ congenic controls. A and B, Schematic
representations of the cortical areas (at 1.22 mm from Bregma) (A) and the cerebellum (Cbl) (at 6.24 mm from Bregma) (B) selected for
planimetry and thickness assessments. The section range values are shown above the illustrations. The hippocampal (Hipp) region outlined in A is
for illustrative purposes only; the actual hippocampal sections measured were at 1.70 mm to 4.16 mm from Bregma. C and D, Comparison of
the brain areas (C) and ventricle area:brain area ratios (D) in each substrain according to age. Results show that a reduced brain area is concomitant
with the onset of lupus-like disease in MRL/lpr mice, and a significantly increased brain area ratio is evident in middle-age MRL/lpr mice. The
section range values used to assess the brain areas and area ratios are shown above the graphs. Bars in C and D show the mean and SEM.   P 	
	 0.05;   P 	 0.001, versus age-matched MRL/ controls. Pir  piriform (cortex); S  sensory (cortex); M1  primary motor (cortex);
LV  lateral ventricle; 3VD  third ventricle dorsal; 4V  fourth ventricle.
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The comparisons of ventricle size among the 3
age groups of MRL/lpr mice and control mice revealed
no significant between-group differences. However, due
to a reduction in mean brain area at the onset of CNS
involvement, the relative ventricle area:brain area ratio
was significantly increased in the middle-age group of
MRL/lpr mice (t[23]  3.966, P 	 0.001 versus age-
matched controls) (Figure 2D).
All age groups of MRL/lpr mice had a thinner
cortex at the secondary and primary levels of the motor
cortex (M2 and M1, respectively) and also had thinner
sensory and piriform cortices compared with controls
(Figures 3A–D). This deficiency was profound in MRL/
lpr mice at young age, but attenuated in adulthood
(substrain-by-age, at M2, F[2,55]  4.266, P  0.019; at
M1, F[2,55]  4.539, P  0.015; at the sensory cortex,
F[2,55]  3.906, P  0.026; at the piriform cortex,
Figure 3. Assessment of cortical thickness in all age groups of MRL/lpr mice and MRL/
control mice in the functional brain regions of the secondary (M2) and primary (M1) motor
cortices (A and B) as well as the sensory (S) cortex (C) and piriform (Pir) cortex (D). Bars show
the mean and SEM.   P 	 0.05 versus age-matched MRL/ control mice.
Figure 4. Area of the hippocampus (A) and cerebellum (B) in all age
groups of MRL/lpr mice and MRL/ control mice. Hippocampal
size was comparable in young MRL/lpr mice, but showed retarded
growth in older MRL/lpr mice, concomitant with the onset of severe
lupus-like disease (A). Cerebellar area was significantly reduced in all
age groups of MRL/lpr mice compared with controls (B). Bars show
the mean and SEM.   P 	 0.01;   P 	 0.05, versus
age-matched MRL/ control mice.
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F[2,55]  4.452, P  0.016). Conversely, the size of the
hippocampus in the MRL substrains was comparable
between each substrain in the young age group (t[9] 
0.209, P NS), but its growth was retarded in the middle-
age and old MRL/lpr groups compared with their age-
matched MRL/ controls (substrain, F[1,55]  7.164,
P 	 0.01) (Figure 4A).
Finally, MRL/lpr mice of all ages had smaller
cerebellums than did their congenic controls, but the
size of the cerebellum increased with age at the same
Figure 5. Representative specimens (shown in horizontal section) used for volumetric assessments by magnetic resonance imaging (MRI),
illustrating the need to account for fluid appearing between the brain and skull. The image in A shows negligible fluid, while in B, significant fluid
buildup is evident. In C and D (expanded views of the sample in A), the cortical surface was estimated without (C) and with (D) suppression of the
fluid signal. In each case, the estimated cortical surface is shown in red. E and F are the corresponding expanded views of the sample in B. Note
the improved estimate of the cortical surface in F. Voxel-wise differences between the brains of MRL/ and MRL/lpr mice are shown in G–L.
Local expansion/contraction factors are shown overlaid on an average of the 31 nonlinearly aligned MRI scans. The local volume difference is
indicated by the scale on the left, with 1.0 corresponding to no difference. Regions significantly smaller in the MRL/lpr group than in the control
group are in blue or purple, and regions significantly larger in the MRL/lpr group are in yellow or red. In G–I, regions shown in color were
significantly different from controls, as determined by Student’s t-test, with t 
 2.6 (degrees of freedom [df] 29), corresponding to a false discovery
rate of 5%. G, Sagittal section to the left of midline. H, Coronal section intersecting the superior and inferior colliculus. I, Transverse section at the
level indicated by the 3-dimensional icon in yellow. Images in G–I show widespread reductions in the brain volume of MRL/lpr mice. In J–L,
corresponding slices show the effect of genotype on brain volume, after correcting for body weight. The threshold for significance (t 
 3.5, df 28)
corresponds to a false discovery rate of 5%. Note the decreases in the volume of the superior and inferior colliculus, periaqueductal gray matter,
and midbrain.
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rate as seen in the control group (substrain, F[1,55] 
128.179, P 	 0.001; age, F[2,55]  7.292, P  0.002)
(Figure 4B). Taken together, the obtained results sug-
gest that the brain of the MRL/lpr mouse is lighter, the
cortex is thinner, and the cerebellum is smaller than that
of the MRL/ substrain. In addition, an increased
ventricle area:brain area ratio and shrinking hippocam-
pus are associated with the development of lupus-like
disease.
Brain volumetric data, as revealed by MRI in
experiment 2. The cohort of MRL/lpr mice obtained
from The Jackson Laboratory was lighter than their
MRL/ controls (mean  SD body weight 43.0  3.5
gm versus 46.6  3.5 gm; P  0.008). Both genotypes
showed a fluid layer around the brain in 40% of
specimens (Figures 5A–F). Consistent with the reduced
brain area observed in experiment 1 in MRL/lpr mice,
the overall brain volume in MRL/lpr mice was smaller
than in MRL/ controls (mean  SD 0.48  0.03 ml
versus 0.52  0.02 ml; P 	 0.008). When these data were
corrected for the difference in body weight, this corre-
sponded to an effect of substrain (genotype) on brain
volume of 0.02 ml. When a false discovery rate of 5%
was assumed, 46 of the 62 structures were found to be
significantly smaller in MRL/lpr mice than in MRL/
congenic control mice, after correcting for body weight.
A complete list of the volumes of each brain structure,
corresponding to anatomic regions defined in the atlas,
is given in Table 1.
A statistical parametric map of local volume
differences revealed a few regions that deviated from the
overall linear trend of smaller brain size in MRL/lpr
mice. The volumes of the superior colliculus, periaque-
ductal gray matter, pons, and midbrain in MRL/lpr mice
were profoundly reduced relative to the overall brain
volume, whereas a bilateral portion of the parietal-
temporal lobe and parts of the cerebellum were less
decreased in volume. This localized pattern was seen
either in analyses without correction for the difference in
body weight (Figures 5G–I) or when this factor was
considered a covariate (Figures 5J–L). In summary, the
MRI analysis revealed a high degree of bilateral symme-
try, a widespread volume reduction in a majority of
regions, and profound effects in areas bordering the
ventricular system in diseased MRL/lpr mice.
DISCUSSION
The present study reveals significant morphologic
changes in the brains of autoimmune MRL/lpr mice.
Reductions in brain parenchyma are evident even at
young age, as characterized by a lower brain mass,
reduced thickness of cortical regions, and smaller cere-
bellum. Moreover, further declines in the overall brain
area and hippocampal size suggest that early pathologic
changes in CNS lupus show progression in adult MRL/
lpr mice. The MRI analysis revealed significantly re-
duced volumes in a majority of brain regions and nuclei,
most notably in the vicinity of the ventricular system.
These findings support the hypothesis that the early
onset of lupus-like disease retards brain growth and
leads to a neurodegenerative phenotype (11,14). More-
over, these results are consistent with evidence that the
emergence of systemic autoimmunity and inflammation
renders cerebrospinal fluid neurotoxic to periventricular
areas of the limbic system, thus producing lesions that
underlie deficits in emotional reactivity and motivated
behavior (15,18,28).
Several mechanisms may account for the ob-
served pathologic changes in the brain before the SLE-
like disease fully manifests. First, MRL/lpr mice have a
dysfunctional Fas receptor in immune and other somatic
cells. The lack of normal apoptotic signaling in the brain
(29) may lead to aberrant embryogenesis and postnatal
development (30). Second, an early up-regulation in
systemic interleukin-6 (31) may compromise the imma-
ture blood–brain barrier and induce detrimental changes
in neurogenesis (32). Last, given that autoimmune dams
are used (at 3–4 months of age) in the production of
MRL/lpr pups, one may assume that full-blown maternal
disease affects normal development of the embryonic
brain. Indeed, CNS involvement in neonatal lupus has
been documented by computed tomography; a majority
of infant mice whose mothers were affected by SLE had
brain abnormalities, including reduced attenuation of
the cerebral white matter, reduced subcortical white
matter, basal ganglia calcifications, and enlarged ventri-
cles (33). Along the same line, experimental studies
revealed that mouse offspring develop profound defi-
ciencies in behavior when wild-type embryos are reared
in an autoimmune uterine environment (34). More
recently, reduced cortical thickness and anti-NMDA
receptor binding in the ventricular zone have been
observed in mouse offspring exposed in utero to neuro-
toxic autoantibodies from dams with lupus-like disease
(35). A teratogenic role of maternal autoantibodies is
also proposed from studies showing the toxicity of
human SLE immunoglobulins on rat embryos (36) and
significant correlation to learning disability in children
of mothers with SLE (37).
In addition to an overall reduction in brain
volume in most brain regions, the limbic and midbrain
structures are particularly reduced in MRL/lpr mice.
The observation of disease-related hippocampal atrophy
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Table 1. Volume of atlas-identified brain structures in autoimmune MRL/lpr mice compared with MRL/ congenic controls
Anatomic region
Volume, mean  SD l
% difference in
volume P*MRL/ MRL/lpr
Colliculus superior 9.28  0.36 8.29  0.46 12.0 0.0005
Pontine nucleus 2.01  0.07 1.83  0.08 9.4 0.0007
Periaqueductal gray 9.42  0.37 8.55  0.42 10.1 0.0012
Pons 29.62  1.08 27.18  1.21 9.0 0.0016
Cerebral aqueduct 1.56  0.05 1.44  0.06 8.4 0.0026
Fourth ventricle 1.07  0.03 0.99  0.05 8.0 0.0026
Interpedunclar nucleus 1.26  0.04 1.17  0.05 7.7 0.0026
Inferior cerebellar peduncle 0.99  0.03 0.91  0.05 8.4 0.0046
Medulla 55.27  2.51 50.49  2.57 9.5 0.0046
Midbrain 22.63  0.97 20.56  1.25 10.0 0.0046
Dentate gyrus of hippocampus 4.35  0.17 4.02  0.21 8.1 0.0057
Stria medullaris 1.14  0.04 1.06  0.05 7.8 0.0057
Cuneate nucleus 1.18  0.04 1.10  0.05 7.3 0.0059
Mammillary bodies 1.30  0.04 1.21  0.06 7.6 0.0059
Posterior commissure 1.14  0.05 1.05  0.05 8.1 0.0059
Superior cerebellar peduncle 1.00  0.04 0.92  0.05 8.5 0.0068
Colliculus inferior 5.25  0.22 4.82  0.28 9.0 0.0068
Facial nerve; cranial nerve 7 1.07  0.04 1.00  0.05 7.5 0.0068
Lateral olfactory tract 1.73  0.07 1.60  0.08 8.0 0.0068
Thalamus 16.70  0.78 15.30  0.87 9.1 0.0085
Middle cerebellar peduncle 1.75  0.06 1.64  0.07 6.4 0.0097
Habenular commissure 0.80  0.03 0.75  0.04 7.5 0.0097
Hippocampus 19.58  0.86 18.12  0.93 8.1 0.0097
Mammilothalamic tract 0.72  0.03 0.67  0.03 7.7 0.0097
Bed nucleus of stria terminalis 1.92  0.08 1.77  0.10 8.4 0.0105
Olfactory bulbs 18.88  0.75 17.64  0.75 7.0 0.0105
Medial lemniscus medial longitudinal fasciculus 2.55  0.14 2.33  0.13 9.5 0.0112
Anterior commissure pars anterior 1.63  0.08 1.50  0.09 9.2 0.0114
Arbor vita of cerebellum 7.93  0.31 7.39  0.37 7.4 0.0132
Stria terminalis 1.39  0.06 1.29  0.07 8.1 0.0142
Third ventricle 2.03  0.08 1.89  0.10 7.2 0.0159
Anterior commissure pars posterior 1.58  0.06 1.47  0.08 7.4 0.0165
Fasciculus retroflexus 1.62  0.06 1.51  0.08 7.2 0.0165
Fornix 1.38  0.06 1.28  0.07 7.7 0.0171
Fimbria 3.65  0.16 3.38  0.19 7.9 0.0171
Superior olivary complex 1.28  0.06 1.18  0.07 8.4 0.0178
Internal capsule 3.03  0.14 2.81  0.17 8.1 0.0179
Subependymale zone rhinocele 0.59  0.02 0.55  0.03 7.3 0.0179
Stratum granulosum of hippocampus 2.38  0.11 2.21  0.13 8.1 0.0190
Ventral tegmental decussation 1.02  0.04 0.95  0.05 7.6 0.0197
Corticospinal tract pyramids 2.29  0.15 2.09  0.12 9.7 0.0219
Inferior olivary complex 0.90  0.04 0.83  0.05 8.5 0.0219
Globus pallidus 3.57  0.15 3.32  0.18 7.4 0.0230
Cerebral peduncle 2.89  0.12 2.69  0.16 7.5 0.0240
Lateral septum 3.44  0.17 3.19  0.18 7.8 0.0297
Corpus callosum 15.60  0.84 14.33  1.01 8.9 0.0450
Occipital lobe 5.75  0.20 5.35  0.37 7.4 0.0510
Optic tract 1.29  0.06 1.20  0.07 7.5 0.0510
Fundus of striatum 1.34  0.06 1.25  0.07 7.0 0.0778
Striatum 22.60  1.38 20.80  1.40 8.7 0.0912
Cerebellar cortex 48.10  1.64 45.49  2.60 5.8 0.0971
Nucleus accumbens 4.59  0.26 4.25  0.29 7.9 0.1194
Medial septum 2.55  0.13 2.38  0.15 7.3 0.1336
Basal forebrain 6.69  0.35 6.22  0.43 7.5 0.1497
Frontal lobe 41.72  2.32 38.85  2.57 7.4 0.1897
Hypothalamus 8.69  0.50 8.11  0.55 7.2 0.2293
Olfactory tubercle 3.73  0.23 3.50  0.24 6.6 0.3489
Pre para subiculum 2.42  0.13 2.26  0.17 7.2 0.3514
Lateral ventricle 3.03  0.16 2.86  0.17 5.7 0.4056
Parieto-temporal lobe 69.04  3.93 65.41  4.11 5.6 0.6501
Amygdala 14.61  0.97 13.93  1.04 4.8 0.6775
Entorhinal cortex 8.73  0.39 8.36  0.46 4.5 0.7275
* P values were determined by t-test, after corrections for body weight and multiple comparisons.
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is not surprising, since this is consistent with the neuro-
degenerative changes observed in SLE patients and in
MRL/lpr mice at the onset of autoimmune disease
(14,15). Immune-mediated mechanisms, such as
antibody-mediated neurotoxicity (28,38), are likely crit-
ical for the terminal damage of brain tissue. Moreover,
an early disturbance in the activity of the hypothalamus–
pituitary–adrenal axis and elevated levels of serum cor-
ticosterone at baseline (39) may play a permissive or
facilitatory role by increasing neuronal vulnerability;
namely, this endocrine imbalance leads to sustained
binding of corticosterone to its receptors in the hip-
pocampus and induces hippocampal dysfunction and
reductions in hippocampal volume, as shown in other
models of chronic disease (40). Along the same line, a
smaller midbrain and hippocampus are consistent with
the notion of an anxious/depression-like behavioral pro-
file (18,20,41), deficits in spatial learning/memory tasks
(42), proclivity to self-injurious behavior, and altered
dopamine receptor expression in substantia nigra of
diseased MRL/lpr mice (43).
The present results add to the face validity of the
MRL model by revealing an aspect that is consistent
with the findings from CNS lupus imaging. In particular,
it is documented that magnetization transfer ratios, an
MRI metric sensitive to the detection of demyelination
and atrophy, are abnormal in patients with CNS lupus
(44), as is water diffusivity assessed by diffusion-
weighted MRI (7). The absence of focal injury in the
MRL/lpr model is consistent with MRI findings in
humans indicating that SLE patients with neuropsychi-
atric symptoms show diffuse brain injury (45) with
evidence of demyelination, axonal loss, and atrophy (46).
A recent clinical study that used quantitative diffusion
imaging and diffusion anisotropy showed decreased an-
isotropy in the genu corpus callosum and anterior inter-
nal capsule of SLE patients (47). Although other
changes may be unique to the anatomy of the human
brain, these observations match the findings of reduced
volumes of corpus callosum and internal capsule in
diseased MRL/lpr mice.
As further evidence of neurodegeneration,
N-acetyl aspartate, a marker of neuronal viability mea-
sured by magnetic resonance spectroscopy (MRS), is
also reduced in CNS lupus (48) and is expressed at lower
levels in patients whose brains show significant atrophy
(49). Similarly, an experimental study that used MRS
revealed increased water content in MRL/lpr brains,
indicative of edema (50). In addition, the levels of
glutamine, glutamate, and lactate were higher in the
brains of MRL/lpr mice than in controls.
In summary, the present study reveals profound
neuroanatomic changes in the lupus-prone MRL/lpr
substrain that are likely mediated by several mecha-
nisms. An age-dependent decline in brain mass and
hippocampal size are consistent with a cascade of patho-
genic events. They include cerebrospinal fluid–mediated
cytotoxicity, impaired neurogenesis, and neurodegen-
eration in the limbic system that accounts for early
changes in emotional reactivity. By providing evidence
of disease-associated damage of the hippocampus and a
periventricular pattern of brain damage, the validity of
the MRL model is further strengthened as a way of
understanding brain damage in patients with SLE.
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